14 november 2018: lees ook dit artikel:

https://kanker-actueel.nl/aspirine-ter-voorkoming-van-kanker-of-een-recidief-van-kanker-een-overzicht-van-studies-met-aspirine.html

27 juli 2016: lees ook dit artikel:

https://kanker-actueel.nl/NL/aspirine-gebruik-na-diagnose-van-darmkanker-geeft-in-vergelijking-met-geen-aspirinegebruik-een-betere-overleving-met-125-procent-op-3-jaars-meting-copy-1.html

27 juli 2016: Een update van het volledige studierapport van onderstaand beschreven studie: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer is gratis in te zien. Onderaan artikel het abstract van deze studie

18 mei 2005: Bron: DOW

Dagelijks 325 mg aspirine voorkomt bij 55% bij de patiënten een recidief van geopereerde darmkanker en van de groep patiënten had 50% minder risico op sterven aan hun darmkanker blijkt uit deelstudie onder 75 van de 847 gevolgde darmkankerpatiënten. Ook VIOXX en CELEBREX gaf gunstigere cijfers te zien maar er waren in deze studiegroep te weinig deelnemende patiënten die dit gebruikten om daaruit conclusies te kunnen trekken. Aspirine na operatie lijkt dus een goedkoop en veilig middeltje om een recidief van darmkanker te voorkomen

-- DJ Regular Aspirin Use May Ward Off Colon Cancer Return -Study --

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES (This article was originally published Monday) ORLANDO, Fla. (Dow Jones)--Cancer researchers found that regular aspirin use cuts the risk of colon cancer recurrence by half, according to research to be presented Tuesday at the American Society of Clinical Oncology's annual meeting. Researchers at Dana-Farber Cancer Institute in Boston, who lead the study, looked at a group of patients that were part of a larger research project studying the use of chemotherapy in colon cancer patients after the cancer was removed by surgery. Aspirin is often recommended as a way to reduce cardiovascular risks like heart attacks and strokes, and previous studies have suggested it cuts the risk of developing colon cancer. The study is the largest to look at risk reduction in patients already diagnosed with colon cancer. Patients were taken from a study of 846 patients who were enrolled in a randomized trial of two chemotherapy regimens following surgery for colon cancer. They all had stage III colon cancer that had spread to lymph nodes, but not elsewhere in the body. The researchers interviewed patients about medication use and lifestyle and found that 75, or 8.9% of patients, reported regular aspirin use. Jeffrey Meyerhardt, an oncologist and one of the study's authors, said aspirin users had a 55% lower risk of having their colon cancer return and a 50% lower risk of death compared with non-users. Most patients either took a 325 milligram tablet every day or every other day, he said. Patients in the study were followed for almost three years. However, Meyerhardt said more study is needed before a specific recommendation to take aspirin can be made to colon cancer patients. He discussed the findings with reporters Monday. Meyerhardt also said 41 patients reported using the COX-2 inhibitor anti-inflammatory drugs Celebrex or Vioxx, and that those drugs also appeared to reduce the risk of having colon cancer return in a manner similar to aspirin. However, he said, the number of patients in the COX-2 group was too small to have the findings reach statistical significance. Merck & Co. (MRK) has since removed Vioxx from the market, after studies showed it increased the risk for heart attacks and strokes. -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;

this observational study of stage III colon cancer patients found statistically significant associations between aspirin and COX-2 inhibitor use and reduced cancer recurrence and mortality.

2014 Nov 27;107(1):345. doi: 10.1093/jnci/dju345. Print 2015 Jan.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Ng K¹, Meyerhardt JA², Chan AT², Sato K², Chan JA², Niedzwiecki D², Saltz LB², Mayer RJ², Benson AB 3rd², Schaefer PL², Whittom R², Hantel A², Goldberg RM², Venook AP², Ogino S², Giovannucci EL², Fuchs CS².

Author information

Abstract

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio = 0.51, 95% confidence interval = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.